Antiphospholipid antibody syndrome
Revision as of 03:02, 19 August 2018 by Warner-admin (talk | contribs) (Text replacement - "{| class="wikitable" style="width: 100%; text-align:center;" !Study !Evidence !Comparator !Efficacy |-" to "{| class="wikitable" style="width: 100%; text-align:center;" !style="width: 25%"|Study !style="width: 25%"|Evidence !style="width: 25%"|Comparator !style="width: 25%"|Efficacy |-")
Section editors | |||
---|---|---|---|
Shruti Chaturvedi, MBBS, MSCI Baltimore, MD |
Benjamin Tillman, MD Nashville, TN |
1 regimens on this page
1 variants on this page
|
Guidelines
To be completed
All lines of therapy
Warfarin monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Crowther et al. 2003 | Phase III (C) | High-intensity Warfarin (INR 3.1 to 4.0) | Seems not superior |
Pengo et al. 2018 | Phase III (C) | Rivaroxaban | Fewer events |
Note: Pengo et al. 2018 was closed prematurely due to excess events in the rivaroxaban arm.
Therapy
- Warfarin (Coumadin) PO titrated to goal INR 2.0 to 3.0
Continued indefinitely
References
- Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003 Sep 18;349(12):1133-8. Erratum in: N Engl J Med. 2004 Jul 8;351(2):200. N Engl J Med. 2003 Dec 25;349(26):2577. link to original article PubMed
- Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffattia A, Andreoli L, Tincani A, Cenci C, Prisco D, Fierro T, Gresele P, Cafolla A, De Micheli V, Ghirarduzzi A, Tosetto A, Falanga A, Martinelli I, Testa S, Barcellona D, Gerosa M, Banzato A. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018 Jul 21. link to original article PubMed